We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Hematology-Oncology

Pre-Diagnostic Low-Normal Immunoglobulin Levels Identify Early Clonal B-cell Dysregulation and CLL Susceptibility: Insights from a Large Retrospective Cohort

MedXY Editorial Team•Aug 20, 2026•Hematology-Oncology
cancer susceptibilityimmunoglobulin levelsmonoclonal B-cell lymphocytosis慢性淋巴细胞白血病,免疫球蛋白水平,单克隆 B 细胞淋巴细胞增多症,癌症易感性

Highlight

This large retrospective cohort study of nearly 295,000 adults reveals distinct predictive roles for low-normal immunoglobulin levels in the development of chronic lymphocytic leukemia (CLL). Low-normal serum IgA uniquely identifies constitutional susceptibility to CLL, while low-normal IgM and IgG reflect prediagnostic tumor burden linked to occult monoclonal B-cell lymphocytosis (MBL). These dual mechanisms provide novel insights into CLL pathogenesis and risk stratification years before clinical diagnosis.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Genetic Risk and Ibrutinib Treatment Outcomes in Early-Stage CLL: Insights from the GCLLSG CLL12 TrialThe GCLLSG CLL12 trial reveals ibrutinib’s event-free survival benefits in specific genetic subgroups of early-stage CLL, while affirming watch-and-wait as standard for high-risk patients with del(17p) and TP53 mutations.Sep 1, 2026Beyond Complexity: Why Molecular Features Still Dictate the Prognosis of Chronic Lymphocytic LeukemiaEmerging data from UK clinical trials indicate that while high genomic complexity (HGC) correlates with poor outcomes in CLL, it often serves as a surrogate for other established high-risk markers like TP53 status and telomere length.Mar 13, 2026Adding Ianalumab to Ibrutinib Induces Deep Remissions and Enables Therapy Discontinuation in Chronic Lymphocytic LeukemiaA Phase Ib study reveals that adding the anti-BAFF-R antibody ianalumab to ibrutinib therapy achieves high rates of undetectable measurable residual disease (uMRD), allowing over 40% of CLL patients to successfully discontinue long-term treJan 13, 2026Advancing Chronic Lymphocytic Leukemia Management: The Impact of Measurable Residual Disease-Guided Ibrutinib-Venetoclax Therapy
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Phase 3 trial data demonstrate that ibrutinib-venetoclax therapy achieves superior undetectable measurable residual disease rates and significantly prolonged progression-free survival compared with ibrutinib alone or FCR in chronic lymphocy
Oct 9, 2025